{"ticker": {"uuid": "8c110582-8542-4b49-ab7e-1baaed1fb970", "symbol": "COLL", "name": "Collegium Pharmaceutical Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Did Collegium Pharmaceutical\u2019s Profitability Surge and Efficiency Gains Just Shift COLL\u2019s Investment Narrative?", "summary": "Collegium Pharmaceutical recently reported strong quarterly results with significant revenue growth and a large increase in net profit, suggesting that operational adjustments are improving earnings. This positive performance, coupled with reaffirmed full-year 2026 revenue guidan", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici", "source_name": "Simply Wall Street", "published_at": "2026-06-21T05:29:06", "published_display": "21 Jun 2026 05:29", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Collegium Pharmaceutical Inc (COLL) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have an average target price of $48.00 for COLL, with a consensus of \"Buy\" based on 6 analysts. The company's expected revenue for the next quarter i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:10:34", "published_display": "19 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Collegium Pharmaceutical Inc (COLL), highlighting its current valuation score, market capitalization, and P/E ratio. The company's valuation score is 8.50, ranking 84 out of 157 in the Pharmaceuticals industry, with a P/E ratio of 14", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T02:10:34", "published_display": "19 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9LeU9KSkpER0NTdkgtV01Ba3ZvdFdIdUVQcXdoMFo1U0VtU2w3Z2dJbHlxUEVvdGdWLWxGbTFqU3N6d0U2RkZBTUpuc1BYODR2ZzBVaGhRWUhtR012SUFKQnZxelBpaWF2cUNiOG52SHBPNUVubjJJ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T23:22:59+00:00", "published_display": "18 Jun 2026 23:22", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBqLXUtb3NwNW9YUUJmdG84WDhPTjJrYVhDYVota1d1V3dkaENEc1lJMWdpLXU2YlVocE8tRk5jUklaMGo2RGkxeUxCX3MzS2FteHZBajlKYWRtcWlQY3BVb1B0eGFfQmNzbmxDOVBNTHhqVFN1TUFQeQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:01:04+00:00", "published_display": "17 Jun 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed breakdown of Collegium Pharmaceutical Inc's (COLL) revenue by business segment and region, using data updated on April 6. The main revenue drivers are Nucynta IR, Belbuca, and Xtampza ER, with all reported revenue originating from the United State", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:57", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and different types of shareholders. It provides a breakdown of the largest shareholders, their proportional ownership, and recent changes in their holdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:57", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (COLL) Volatility", "summary": "This article analyzes Collegium Pharmaceutical Inc. (NASDAQ: COLL) volatility using AI models, identifying a mid-channel oscillation pattern and an exceptional 86.1:1 risk-reward setup. It outlines specific position, momentum, and risk-hedging trading strategies, along with multi", "url": "https://news.stocktradersdaily.com/news_release/1/Trading_Systems_Reacting_to_COLL_Volatility_061426120802_1781453282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-14T11:39:40", "published_display": "14 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] COLLEGIUM PHARMACEUTICAL, INC Insider Trading Activity", "summary": "COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of common stock at $16.49 per share. Following this transaction, Santini directly holds 112,483 shares of common stock, and the exercised option is fully utilized. The Form 4 filin", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-9d8e4f03f1a9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:40:33", "published_display": "10 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLEGIUM PHARMACEUTICAL (COLL) director exercises options, now holds 112,483 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOekIyb0tocXBla3I4Wld2S0g5dkxqT1VBYWVQWUxqZjJ5QnZuYV85Wm5HRFlHLWtPWVJ4U3FDQlN2QzNBaGt0dVYtUFdCZ3FOTC1fdlNoWE5XTF9HV3JxUlVBdmkxc2pKX3ZmOTNPT1c5cTNPYmVoZGJIX1ZVSTNQalhFV3Zld3RXd1hfajNaUGhlQUtNYU1WMERYNHZUeFFYZGJaQmY1eWw1THhlLWM5czVyQng3TGZzNVFzMWtHTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (Nasdaq:COLL) - Stock Analysis", "summary": "This report provides an in-depth stock analysis of Collegium Pharmaceutical (Nasdaq:COLL), highlighting its current market valuation, future growth prospects, past performance, and financial health. The company is currently trading 36.7% below its estimated fair value with earnin", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical", "source_name": "Simply Wall Street", "published_at": "2026-06-08T01:38:58", "published_display": "08 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL: Steady 2026 Earnings Guidance Will Support Undervalued Affordable Medicines Theme", "summary": "Collegium Pharmaceutical (COLL) has reaffirmed its full-year 2026 earnings guidance, projecting product revenues between US$805 million and US$825 million. Analysts have maintained their price target of US$54.33, indicating that the stock is considered 38.6% undervalued based on ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot/updates/23-analysts-kept-their-dollar5433-price-target-for-collegium-pharma", "source_name": "Simply Wall Street", "published_at": "2026-06-08T01:09:10", "published_display": "08 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Collegium Pharmaceutical, Inc. announced that it granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, under its 2026 Inducement Plan. These grants serve as a material inducement for their employment, in accordance with Nasdaq Lis", "url": "https://finance.yahoo.com/markets/stocks/articles/collegium-pharmaceutical-reports-inducement-grants-120000115.html", "source_name": "Market source", "published_at": "2026-06-07T15:10:21", "published_display": "07 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOZm5RYWNXcWhxcGtiOFZqVjJUSk5MRGZKeUFjSmw5MHRlVGhkZEZISDlSclk5cTVSSDJmMXR4YUpLei1wY1VyVXpWY1o1SnQxZ0Q0YV9TUllKbDZ3YzN3QlR4MXI3S1NVUXdWRTVRYVFNUEh1RTZWbzhpRnJHR3ZoMFF5N1dKZVY5eVljaDdQbXlqUVlxUHd0WXVyU2NiODRVUkp5RmhYY2h1Tkk1dndFVFFhejQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL - Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success", "summary": "Collegium Pharmaceutical's fair value has been slightly increased to $54.33, reflecting updated assumptions regarding revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance, projecting product revenues between $805 million and $82", "url": "https://simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot?bpId=4519252&link_type=cta_narrative_prompt_after_quote", "source_name": "Simply Wall Street", "published_at": "2026-05-29T21:40:02", "published_display": "29 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium to Participate in 2026 Jefferies Global Healthcare Conference", "summary": "Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET. The company, focused on CNS and pain conditions, will webcast the event live, with a replay available for 90 days. This particip", "url": "https://www.globenewswire.com/news-release/2026/05/27/3301845/0/en/Collegium-to-Participate-in-2026-Jefferies-Global-Healthcare-Conference.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:40:13", "published_display": "27 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Nears Key Support After Modest Decline - Growth Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZ3YycjA5ekdOWmJaSUJhUXdLQ1g1NTd0dkQzbXFWOUlKMDJvTGpJaWFzcUdRdGJucFZvNkRHVC1hMmM3TzNzNDdKdEtTRDhHcWRtVGRMOHAzbUZtSHVtanppQ0tGS2w5TmotbVIybHg5Z0l3a1htUXV5UENJdk1Na2hteHlzNjRsYnBkN2RzWGwtTmdHX3d4U0F5VW5pbEt3eTB6aWU0ZUNJSkE?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors can stream Collegium's Jefferies healthcare fireside chat live", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZVAwT1JWLTdnRmhzY0xaTldXYldLZER4TXRDaTRKenphaGhlbTJDR19hMnpPU3R4ejI2VkNQU0t4ZWVSejdWb2lzOE1uMnRFT3hSUzZYSGtoRkhjVk9MZ1NyaTQzTEtKVTRXWEZtSVhyZDdqY1VFSS1YRUREZEJaa1paUE5ZeC1QdmgyQjhlTDhFRGhuYkxWdUgtSFBVYWYtQUQzTkF6ellJSWdvbnZUXzZRTXNFQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQOXZPQmFpNnpRWEJHVDZZX3FZN3AyRVpaX2RBd0o1NDFUU3kwbVRRVFI3VnRYc05FNXFieHU4dm8wQjlWZEx4RVdVZmJ3SkJyR2U1bml3ZEJRSkhGR2t4RDdkM191VnNHcFUwVm83TzJtX0FuT3ZsX1A0b0dLR1g1OWVjcktpMWo3aWdBTUlwdWFvMUJNQWhKODhzdmp4cHZKdkxpNTRqS09DdGU2YXUzaVczYw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story", "summary": "Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks. ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/how-strong-q1-earnings-and-executive-departures-at-collegium", "source_name": "Simply Wall Street", "published_at": "2026-05-21T21:10:00", "published_display": "21 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL: Consistent 2026 Earnings Guidance Will Support Affordable Medicines Theme Upside", "summary": "Collegium Pharmaceutical's fair value has been slightly increased by analysts, moving from $54.17 to $54.33, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance for product revenues, net, in the", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot/updates/22-analysts-have-lifted-their-price-target-on-collegium-pharmac", "source_name": "Simply Wall Street", "published_at": "2026-05-21T09:10:00", "published_display": "21 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952", "summary": "Collegium Pharmaceutical director John Gordon Freund reported selling 20 common shares at $34.05 each on May 18, 2026, in an open-market transaction. Following this sale, he directly holds 83,952 common shares and also has indirect interests in additional shares through affiliate", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-dc0d3c224441.html", "source_name": "Stock Titan", "published_at": "2026-05-20T19:40:14", "published_display": "20 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)", "summary": "Collegium Pharmaceutical director Nancy Lurker was granted 8,741 restricted stock units (RSUs) as part of her compensation, with each RSU representing one share of common stock. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 annual shareholder meeting,", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-a24d8512ac3a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:10:15", "published_display": "19 May 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium (COLL) director sells shares, exercises options and receives RSU grant", "summary": "Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional ", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-8870f3067cf9.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award", "summary": "Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company\u2019s 2027 Annual Meeting of Shareholders, provided she continues her service as a", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-fac405c55e2a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3", "summary": "Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or deri", "url": "https://www.stocktitan.net/sec-filings/COLL/form-3-collegium-pharmaceutical-inc-initial-statement-of-beneficial-o-fb31292955c6.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant", "summary": "Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he c", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-5d6bd12b0ca6.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)", "summary": "COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, cont", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-f6106f9b54eb.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (COLL) awarded 17,482 restricted stock units", "summary": "Collegium Pharmaceutical director Michael Glancy was granted 17,482 restricted stock units (RSUs) on May 14, 2026, at no cash cost. These RSUs will vest in two equal tranches on or around May 14, 2027, contingent on his continued service to the board. Following this grant, Glancy", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-8359a4c41184.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium pharmaceutical director sells $142k in shares", "summary": "A director at Collegium Pharmaceutical, John Gordon Freund, recently sold shares worth $142,546 and exercised stock options on May 14 and 15, 2026. Despite the stock being down 27% year-to-date, it has risen 12% over the past year. The company also reported strong Q1 2026 financi", "url": "https://m.investing.com/news/insider-trading-news/collegium-pharmaceutical-director-sells-142k-in-shares-93CH-4696911?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares", "summary": "Collegium Pharmaceutical director Garen G. Bohlin was granted 8,741 Restricted Stock Units (RSUs), increasing his direct holdings to 71,000 shares. These RSUs, which represent one share of common stock each, will vest on the earlier of May 14, 2027, or the company's 2027 Annual M", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-374d39c2c47d.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Collegium Pharmaceutical Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPX0RSWlV0UFJ5SDNlUzhSNkRVSW9WZkUtTnNsUmRmYlRoWW9QdXhmUzFQTFJUVlpUZEhjc1c2SEowZi12LXNaZVNTYktwVzJBeFFqbXdHQzVKY2JsMWZWRlZjdTg5YWNDcUxVVE1LczVmMWhVQlZMVTZTVWF0NFg5SldPMTh2SlJpbU56a2VQZnhQSUFfdnJuZW04bkg2cUtmV0VfTzBsUEk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADHD drug JORNAY jumps 36% as Collegium nears $650M AZSTARYS buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNbk9IM2s5UTYzT19JS0haNm1iNHlpXzhMSDQ3T0FfazFjSWZ2MVpVcVJhbTJaS3JJM201WGw5a3dPRFphOE9UYS12RGMxQlA4Nl9Ma2JiSXg5dk5LYWViTHdyQUN0SERJdE8zeTJvRktOQUtJUG9oUFRQZ3hXaTAxdDB3TU4tTHA1WER1UGh6RUdBN2U4eVNRRGpEdTlMSXZiR3lJY1FJcnF5OTgtR3hNSEJ2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0ZjYmt4eGUtcksxQW9QTUVJeG9DOTVlTlVsemF1MkFaX1lYMmdReXduNjBCbVJjNG5oUDJTTHQ4cWF5T04tczVhUi00bl8tM2twMnRZcS1EMG5HVnFESU1GOF85U3Z6SGJlbTFVSzNYVDhLdkF5bjVsU0pTTjJwXzB4UlJ0c0FSVENkSXRfS1FRRDZPRkZES0k5WnZNX2drZktzOUZ5dFdBbDg2RVkw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQmlMYzA5MlVfNkVCUlowai1ZM2J3Nk5ld0RRb1NvbWQ5Vmk2S29vb0wxeUtMMVFHenp3UE40RkZNWW5ZejZVOGUyUEVxMW04X1JYcHZjdUdYNWNfQ0tsTHJ6YTFPTl9TVHBxM2dsUUc5SWRMbVJHa2Z1MGt0b0VYTW5sdTFCNE9EWTdzRFZIcU9FUjNyQlRaRVBHam9ZTHBpZGNfSWdRQnE3bmhnbUVTZEpDSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMjlfUFdIZFFzekUtc2IydEw0LWtZTlhCb212MXpidURfVWhWSW5pdHlwekJ4ZEo5Nmo3TFN6NHZpcnlPMzA3dkFCelZuNGNTZmZrZnVGX1hKc05MdXpsOHJ4OG5EcEo2M3ZIXzZnNWRycFZ3X2FpVTFxTll2ZS0ycnJmaEFpa0JvVnpOWUc1QUtheV9aN3RGWXFSME9wRGdCZXFGcmpqdzFrUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORndraFNoUk8zZFZVQlQ1Mkktc1VZdjRiNjRWOWxkRFlEZVB1MldqS2w4U096U1NpUmRQNWNuQ3ItSTdDeTNLakRvRWRnQXdxRGU1UEQ5ckFpdll6eVp1b25ORU9rOFNSd0NvUmNXcnVrZl9MV2Q5RWtwWDdrdG9qWFhfZ3BDVVRPS1BwS0NYRWFncGFJUFJkdzlNZlUydEdiQzV1STZDNk9mUzY1YlJNRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNalQwUXRNTU9DQk9FX0ExcUs4WWRNLXRqY3lDSEIzalNsVUVmeDk5c2lBZm5jLTFOb0tFNHY3MnhsUXc0d3ppSk0zTTVDNU1saXFSV3FGcDZFb3plNGgwREIzNnMxWkI3SUJGTlRNRTlXZWZLMEVNRFpHQjdWUGxfT0Z4Yi00RFBYYnRRS0xpdEsxbGVja01iLVFPWXQ5Rnhydmswa0I1dnBETjkxdTRz?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$650M ADHD deal gives Collegium a drug with patents into 2037", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOc25QMFJHQWlYX1dFb1FEWWFTclFkN1liZUw1Mzh6ckJ0bks0NWMwT0FfMkVDbTBCdVRtZ1hiamthclluZktoOUwzb3dJWnlibDBxdkNvazBRcUNWTV9ROWJiY3E3RThjNmxpSEpzcmRwZ294VUV2UXhScXlBU3Mya2pOSDQxZ0d2eWNRTTY1Tk1SSTRIS05Rc0IzajZ0ZVhYV0V0Tl9ZVkl3Zk9xNUF3ZkZNVlhoZ1l3Vms1b2dRQVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTzVIRzg0NjFESnpYQVMtU2hQMmdEWDc5QzVrcUx0bWhzTVoxQVVQNUZtRElUQThDWU16X1lDSTJpd3BWVjJ1YUhxa1RIS2VPM0t1ajEwc2RweHN0VlcwN2lIaWZZdHlmVmduMHZmeklOQzJuVHoxS3cySnNHUlFuOTc5eVNGSWhhRWRZWEVR?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPaF9VUmlRLWdoU3c1MjBxaGpDLWc3b0hLZGZtTHpERWdJN0picEdxM3QySFA5aEdVM3l6SG50SXN3TDFYa09ZN01nUmhvOTBnUkdQdkI0a1N3RGlGZV9aRnlGTFJnQ0VBOEZMcjBtVEFiNk1xMmZBQ1lZWlpuX2lUSDVzRDNnX0V2bC1PZw?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Stock: Buying The Projected Growth For 2026 (NASDAQ:COLL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPWWktUDl5c3B5aHRfSXlvZEJJR3lmRXpSbVduNlVZZlZoZjBoV2wwSGVrSF9xY2YtVnpRd3hXQzZ4eUcxWEVodDlBSml3MW1jcHVzV3ZsMTRDUGcyX2hIeERyMGFTNFhYLXJBZ2diekp5dEgyV2VHUmNSUlV4andTVzE3VEJOMVVJdi1mWFQzaFNrZ1BBSnpmZUZiSGFWbk5leTlKZQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9aS3psWlk5LUtNdklxeVhrQ25UeFhsTk50QTdjekY2UTJJcWxDYnZGTkRjTkJEVGhHOFlBUWk0MGR4dkkySGF1LWtIY1F3ZWNRT05GR1JlOA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:38:59+00:00", "published_display": "13 Jan 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Provides 2026 Financial Guidance and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYjltV0MzeWRhUU9nclQtdlBjbllpdlplTURka1B1VmRCNmtoX3dtUVBvR3dhWFkxeFRBaG5QS2lEWC1fQVhwNlBPUGlLbWtGSWZpa1l6SnM4Tlc4RDhtNkF4MFVEYmRna1p5VHFaNnNiOHZNNnBXcE5fcl84ODNGbzlkVlotcmwxZGZCOGk3Q1d5SDk5UzhNdVdic2luV0hIWDY1ZXRyTVV6U0tRWGdtSTdUZzRpckVzS2U3SE9TT0lyWFpHR2xEWThoeWJSUWs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Expands Shareholder Returns With Fresh $150M Stock Buyback After Returning $222M Since 2021", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQOFZJUU1YdFdpbzI1Wk56UFlBbC1vaU1zLVcxTV9jd1pVdXRROWo4NlNaSGlPejYxN1pVN3pieFBpTVpCSVQwejFnX0J2TFNZU2FJYnJjQTBHRmhiMHRrMjNTN2g3ZzRuSmtVQ2tKWF9fUmVhQ2FYUjVfRmlJR0k0aE1DdE5ycmtiQ0JrYkR0SW05VURBUnNIakNOX1d1MFNRMkxacnZB?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-07T07:00:00+00:00", "published_display": "07 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical, Inc._December 31, 2024", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNl8wZHJxUGtLRUp1VmNpbVRzdWw3SVpBZlV0TkM5NnVpc1RyZ1RCZzdodm1iOF9fRE85R2I2N3ZqUHNWRkZVejVQQXhaV2hYNGpWV0xLSGNxUnN3dE1uZks4UkU2aUFPcTZubEtDY0pTYlNmNHgweGRycy1xRTV3TEJtMVFNZ2NuMGd3SW10TlFnQQ?oc=5", "source_name": "SEC.gov", "published_at": "2025-02-27T23:31:13+00:00", "published_display": "27 Feb 2025 23:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Did Collegium Pharmaceutical\u2019s Profitability Surge and Efficiency Gains Just Shift COLL\u2019s Investment Narrative?", "summary": "Collegium Pharmaceutical recently reported strong quarterly results with significant revenue growth and a large increase in net profit, suggesting that operational adjustments are improving earnings. This positive performance, coupled with reaffirmed full-year 2026 revenue guidan", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/did-collegium-pharmaceuticals-profitability-surge-and-effici", "source_name": "Simply Wall Street", "published_at": "2026-06-21T05:29:06", "published_display": "21 Jun 2026 05:29", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Collegium Pharmaceutical Inc (COLL) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have an average target price of $48.00 for COLL, with a consensus of \"Buy\" based on 6 analysts. The company's expected revenue for the next quarter i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:10:34", "published_display": "19 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Collegium Pharmaceutical Inc (COLL), highlighting its current valuation score, market capitalization, and P/E ratio. The company's valuation score is 8.50, ranking 84 out of 157 in the Pharmaceuticals industry, with a P/E ratio of 14", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T02:10:34", "published_display": "19 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9LeU9KSkpER0NTdkgtV01Ba3ZvdFdIdUVQcXdoMFo1U0VtU2w3Z2dJbHlxUEVvdGdWLWxGbTFqU3N6d0U2RkZBTUpuc1BYODR2ZzBVaGhRWUhtR012SUFKQnZxelBpaWF2cUNiOG52SHBPNUVubjJJ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T23:22:59+00:00", "published_display": "18 Jun 2026 23:22", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBqLXUtb3NwNW9YUUJmdG84WDhPTjJrYVhDYVota1d1V3dkaENEc1lJMWdpLXU2YlVocE8tRk5jUklaMGo2RGkxeUxCX3MzS2FteHZBajlKYWRtcWlQY3BVb1B0eGFfQmNzbmxDOVBNTHhqVFN1TUFQeQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:01:04+00:00", "published_display": "17 Jun 2026 21:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed breakdown of Collegium Pharmaceutical Inc's (COLL) revenue by business segment and region, using data updated on April 6. The main revenue drivers are Nucynta IR, Belbuca, and Xtampza ER, with all reported revenue originating from the United State", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:57", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Collegium Pharmaceutical Inc (COLL), outlining major institutional holdings and different types of shareholders. It provides a breakdown of the largest shareholders, their proportional ownership, and recent changes in their holdin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-coll/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:57", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (COLL) Volatility", "summary": "This article analyzes Collegium Pharmaceutical Inc. (NASDAQ: COLL) volatility using AI models, identifying a mid-channel oscillation pattern and an exceptional 86.1:1 risk-reward setup. It outlines specific position, momentum, and risk-hedging trading strategies, along with multi", "url": "https://news.stocktradersdaily.com/news_release/1/Trading_Systems_Reacting_to_COLL_Volatility_061426120802_1781453282.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-14T11:39:40", "published_display": "14 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] COLLEGIUM PHARMACEUTICAL, INC Insider Trading Activity", "summary": "COLLEGIUM PHARMACEUTICAL, INC director Gino Santini exercised stock options to acquire 8,700 shares of common stock at $16.49 per share. Following this transaction, Santini directly holds 112,483 shares of common stock, and the exercised option is fully utilized. The Form 4 filin", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-9d8e4f03f1a9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:40:33", "published_display": "10 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLLEGIUM PHARMACEUTICAL (COLL) director exercises options, now holds 112,483 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOekIyb0tocXBla3I4Wld2S0g5dkxqT1VBYWVQWUxqZjJ5QnZuYV85Wm5HRFlHLWtPWVJ4U3FDQlN2QzNBaGt0dVYtUFdCZ3FOTC1fdlNoWE5XTF9HV3JxUlVBdmkxc2pKX3ZmOTNPT1c5cTNPYmVoZGJIX1ZVSTNQalhFV3Zld3RXd1hfajNaUGhlQUtNYU1WMERYNHZUeFFYZGJaQmY1eWw1THhlLWM5czVyQng3TGZzNVFzMWtHTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (Nasdaq:COLL) - Stock Analysis", "summary": "This report provides an in-depth stock analysis of Collegium Pharmaceutical (Nasdaq:COLL), highlighting its current market valuation, future growth prospects, past performance, and financial health. The company is currently trading 36.7% below its estimated fair value with earnin", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical", "source_name": "Simply Wall Street", "published_at": "2026-06-08T01:38:58", "published_display": "08 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL: Steady 2026 Earnings Guidance Will Support Undervalued Affordable Medicines Theme", "summary": "Collegium Pharmaceutical (COLL) has reaffirmed its full-year 2026 earnings guidance, projecting product revenues between US$805 million and US$825 million. Analysts have maintained their price target of US$54.33, indicating that the stock is considered 38.6% undervalued based on ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot/updates/23-analysts-kept-their-dollar5433-price-target-for-collegium-pharma", "source_name": "Simply Wall Street", "published_at": "2026-06-08T01:09:10", "published_display": "08 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Collegium Pharmaceutical, Inc. announced that it granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, under its 2026 Inducement Plan. These grants serve as a material inducement for their employment, in accordance with Nasdaq Lis", "url": "https://finance.yahoo.com/markets/stocks/articles/collegium-pharmaceutical-reports-inducement-grants-120000115.html", "source_name": "Market source", "published_at": "2026-06-07T15:10:21", "published_display": "07 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOZm5RYWNXcWhxcGtiOFZqVjJUSk5MRGZKeUFjSmw5MHRlVGhkZEZISDlSclk5cTVSSDJmMXR4YUpLei1wY1VyVXpWY1o1SnQxZ0Q0YV9TUllKbDZ3YzN3QlR4MXI3S1NVUXdWRTVRYVFNUEh1RTZWbzhpRnJHR3ZoMFF5N1dKZVY5eVljaDdQbXlqUVlxUHd0WXVyU2NiODRVUkp5RmhYY2h1Tkk1dndFVFFhejQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL - Specialty Pharmaceuticals And Diversified Assets Will Drive Future Success", "summary": "Collegium Pharmaceutical's fair value has been slightly increased to $54.33, reflecting updated assumptions regarding revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance, projecting product revenues between $805 million and $82", "url": "https://simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot?bpId=4519252&link_type=cta_narrative_prompt_after_quote", "source_name": "Simply Wall Street", "published_at": "2026-05-29T21:40:02", "published_display": "29 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium to Participate in 2026 Jefferies Global Healthcare Conference", "summary": "Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET. The company, focused on CNS and pain conditions, will webcast the event live, with a replay available for 90 days. This particip", "url": "https://www.globenewswire.com/news-release/2026/05/27/3301845/0/en/Collegium-to-Participate-in-2026-Jefferies-Global-Healthcare-Conference.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:40:13", "published_display": "27 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Nears Key Support After Modest Decline - Growth Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZ3YycjA5ekdOWmJaSUJhUXdLQ1g1NTd0dkQzbXFWOUlKMDJvTGpJaWFzcUdRdGJucFZvNkRHVC1hMmM3TzNzNDdKdEtTRDhHcWRtVGRMOHAzbUZtSHVtanppQ0tGS2w5TmotbVIybHg5Z0l3a1htUXV5UENJdk1Na2hteHlzNjRsYnBkN2RzWGwtTmdHX3d4U0F5VW5pbEt3eTB6aWU0ZUNJSkE?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors can stream Collegium's Jefferies healthcare fireside chat live", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQZVAwT1JWLTdnRmhzY0xaTldXYldLZER4TXRDaTRKenphaGhlbTJDR19hMnpPU3R4ejI2VkNQU0t4ZWVSejdWb2lzOE1uMnRFT3hSUzZYSGtoRkhjVk9MZ1NyaTQzTEtKVTRXWEZtSVhyZDdqY1VFSS1YRUREZEJaa1paUE5ZeC1QdmgyQjhlTDhFRGhuYkxWdUgtSFBVYWYtQUQzTkF6ellJSWdvbnZUXzZRTXNFQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQOXZPQmFpNnpRWEJHVDZZX3FZN3AyRVpaX2RBd0o1NDFUU3kwbVRRVFI3VnRYc05FNXFieHU4dm8wQjlWZEx4RVdVZmJ3SkJyR2U1bml3ZEJRSkhGR2t4RDdkM191VnNHcFUwVm83TzJtX0FuT3ZsX1A0b0dLR1g1OWVjcktpMWo3aWdBTUlwdWFvMUJNQWhKODhzdmp4cHZKdkxpNTRqS09DdGU2YXUzaVczYw?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story", "summary": "Collegium Pharmaceutical reported strong Q1 2026 net income and reaffirmed its full-year product revenue guidance, signaling continued commercial momentum. However, upcoming departures of its Chief Commercial Officer and Chief Medical Officer introduce potential execution risks. ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/how-strong-q1-earnings-and-executive-departures-at-collegium", "source_name": "Simply Wall Street", "published_at": "2026-05-21T21:10:00", "published_display": "21 May 2026 21:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COLL: Consistent 2026 Earnings Guidance Will Support Affordable Medicines Theme Upside", "summary": "Collegium Pharmaceutical's fair value has been slightly increased by analysts, moving from $54.17 to $54.33, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company reaffirmed its 2026 earnings guidance for product revenues, net, in the", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot/updates/22-analysts-have-lifted-their-price-target-on-collegium-pharmac", "source_name": "Simply Wall Street", "published_at": "2026-05-21T09:10:00", "published_display": "21 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952", "summary": "Collegium Pharmaceutical director John Gordon Freund reported selling 20 common shares at $34.05 each on May 18, 2026, in an open-market transaction. Following this sale, he directly holds 83,952 common shares and also has indirect interests in additional shares through affiliate", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-dc0d3c224441.html", "source_name": "Stock Titan", "published_at": "2026-05-20T19:40:14", "published_display": "20 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)", "summary": "Collegium Pharmaceutical director Nancy Lurker was granted 8,741 restricted stock units (RSUs) as part of her compensation, with each RSU representing one share of common stock. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 annual shareholder meeting,", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-a24d8512ac3a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:10:15", "published_display": "19 May 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium (COLL) director sells shares, exercises options and receives RSU grant", "summary": "Collegium Pharmaceutical director John Gordon Freund recently sold 4,127 shares of common stock, exercised options for 8,700 shares, and received a grant of 8,741 restricted stock units (RSUs). After these transactions, his direct holdings stand at 83,972 shares, with additional ", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-8870f3067cf9.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award", "summary": "Collegium director Rita J. Balice-Gordon was granted 8,741 Restricted Stock Units (RSUs), increasing her direct holdings to 61,370 shares. These RSUs vest on the earlier of May 14, 2027, or the company\u2019s 2027 Annual Meeting of Shareholders, provided she continues her service as a", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-fac405c55e2a.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3", "summary": "Collegium Pharmaceutical (COLL) director Donovan Michael Glancy has filed an initial Form 3, indicating his start as a reporting person for the company. This filing discloses his initial ownership of Collegium Pharmaceutical securities but does not report any transactions or deri", "url": "https://www.stocktitan.net/sec-filings/COLL/form-3-collegium-pharmaceutical-inc-initial-statement-of-beneficial-o-fb31292955c6.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant", "summary": "Collegium Pharmaceutical director Gino Santini was granted 8,741 restricted stock units (RSUs) on May 14, 2026, as an equity award with a $0.00 purchase price. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, provided he c", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-5d6bd12b0ca6.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)", "summary": "COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, cont", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-f6106f9b54eb.html", "source_name": "Stock Titan", "published_at": "2026-05-19T04:08:50", "published_display": "19 May 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Collegium (COLL) awarded 17,482 restricted stock units", "summary": "Collegium Pharmaceutical director Michael Glancy was granted 17,482 restricted stock units (RSUs) on May 14, 2026, at no cash cost. These RSUs will vest in two equal tranches on or around May 14, 2027, contingent on his continued service to the board. Following this grant, Glancy", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-8359a4c41184.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium pharmaceutical director sells $142k in shares", "summary": "A director at Collegium Pharmaceutical, John Gordon Freund, recently sold shares worth $142,546 and exercised stock options on May 14 and 15, 2026. Despite the stock being down 27% year-to-date, it has risen 12% over the past year. The company also reported strong Q1 2026 financi", "url": "https://m.investing.com/news/insider-trading-news/collegium-pharmaceutical-director-sells-142k-in-shares-93CH-4696911?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares", "summary": "Collegium Pharmaceutical director Garen G. Bohlin was granted 8,741 Restricted Stock Units (RSUs), increasing his direct holdings to 71,000 shares. These RSUs, which represent one share of common stock each, will vest on the earlier of May 14, 2027, or the company's 2027 Annual M", "url": "https://www.stocktitan.net/sec-filings/COLL/form-4-collegium-pharmaceutical-inc-insider-trading-activity-374d39c2c47d.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:08:50", "published_display": "18 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Collegium Pharmaceutical Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPX0RSWlV0UFJ5SDNlUzhSNkRVSW9WZkUtTnNsUmRmYlRoWW9QdXhmUzFQTFJUVlpUZEhjc1c2SEowZi12LXNaZVNTYktwVzJBeFFqbXdHQzVKY2JsMWZWRlZjdTg5YWNDcUxVVE1LczVmMWhVQlZMVTZTVWF0NFg5SldPMTh2SlJpbU56a2VQZnhQSUFfdnJuZW04bkg2cUtmV0VfTzBsUEk?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADHD drug JORNAY jumps 36% as Collegium nears $650M AZSTARYS buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNbk9IM2s5UTYzT19JS0haNm1iNHlpXzhMSDQ3T0FfazFjSWZ2MVpVcVJhbTJaS3JJM201WGw5a3dPRFphOE9UYS12RGMxQlA4Nl9Ma2JiSXg5dk5LYWViTHdyQUN0SERJdE8zeTJvRktOQUtJUG9oUFRQZ3hXaTAxdDB3TU4tTHA1WER1UGh6RUdBN2U4eVNRRGpEdTlMSXZiR3lJY1FJcnF5OTgtR3hNSEJ2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0ZjYmt4eGUtcksxQW9QTUVJeG9DOTVlTlVsemF1MkFaX1lYMmdReXduNjBCbVJjNG5oUDJTTHQ4cWF5T04tczVhUi00bl8tM2twMnRZcS1EMG5HVnFESU1GOF85U3Z6SGJlbTFVSzNYVDhLdkF5bjVsU0pTTjJwXzB4UlJ0c0FSVENkSXRfS1FRRDZPRkZES0k5WnZNX2drZktzOUZ5dFdBbDg2RVkw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQmlMYzA5MlVfNkVCUlowai1ZM2J3Nk5ld0RRb1NvbWQ5Vmk2S29vb0wxeUtMMVFHenp3UE40RkZNWW5ZejZVOGUyUEVxMW04X1JYcHZjdUdYNWNfQ0tsTHJ6YTFPTl9TVHBxM2dsUUc5SWRMbVJHa2Z1MGt0b0VYTW5sdTFCNE9EWTdzRFZIcU9FUjNyQlRaRVBHam9ZTHBpZGNfSWdRQnE3bmhnbUVTZEpDSQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMjlfUFdIZFFzekUtc2IydEw0LWtZTlhCb212MXpidURfVWhWSW5pdHlwekJ4ZEo5Nmo3TFN6NHZpcnlPMzA3dkFCelZuNGNTZmZrZnVGX1hKc05MdXpsOHJ4OG5EcEo2M3ZIXzZnNWRycFZ3X2FpVTFxTll2ZS0ycnJmaEFpa0JvVnpOWUc1QUtheV9aN3RGWXFSME9wRGdCZXFGcmpqdzFrUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORndraFNoUk8zZFZVQlQ1Mkktc1VZdjRiNjRWOWxkRFlEZVB1MldqS2w4U096U1NpUmRQNWNuQ3ItSTdDeTNLakRvRWRnQXdxRGU1UEQ5ckFpdll6eVp1b25ORU9rOFNSd0NvUmNXcnVrZl9MV2Q5RWtwWDdrdG9qWFhfZ3BDVVRPS1BwS0NYRWFncGFJUFJkdzlNZlUydEdiQzV1STZDNk9mUzY1YlJNRQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNalQwUXRNTU9DQk9FX0ExcUs4WWRNLXRqY3lDSEIzalNsVUVmeDk5c2lBZm5jLTFOb0tFNHY3MnhsUXc0d3ppSk0zTTVDNU1saXFSV3FGcDZFb3plNGgwREIzNnMxWkI3SUJGTlRNRTlXZWZLMEVNRFpHQjdWUGxfT0Z4Yi00RFBYYnRRS0xpdEsxbGVja01iLVFPWXQ5Rnhydmswa0I1dnBETjkxdTRz?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$650M ADHD deal gives Collegium a drug with patents into 2037", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOc25QMFJHQWlYX1dFb1FEWWFTclFkN1liZUw1Mzh6ckJ0bks0NWMwT0FfMkVDbTBCdVRtZ1hiamthclluZktoOUwzb3dJWnlibDBxdkNvazBRcUNWTV9ROWJiY3E3RThjNmxpSEpzcmRwZ294VUV2UXhScXlBU3Mya2pOSDQxZ0d2eWNRTTY1Tk1SSTRIS05Rc0IzajZ0ZVhYV0V0Tl9ZVkl3Zk9xNUF3ZkZNVlhoZ1l3Vms1b2dRQVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTzVIRzg0NjFESnpYQVMtU2hQMmdEWDc5QzVrcUx0bWhzTVoxQVVQNUZtRElUQThDWU16X1lDSTJpd3BWVjJ1YUhxa1RIS2VPM0t1ajEwc2RweHN0VlcwN2lIaWZZdHlmVmduMHZmeklOQzJuVHoxS3cySnNHUlFuOTc5eVNGSWhhRWRZWEVR?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPaF9VUmlRLWdoU3c1MjBxaGpDLWc3b0hLZGZtTHpERWdJN0picEdxM3QySFA5aEdVM3l6SG50SXN3TDFYa09ZN01nUmhvOTBnUkdQdkI0a1N3RGlGZV9aRnlGTFJnQ0VBOEZMcjBtVEFiNk1xMmZBQ1lZWlpuX2lUSDVzRDNnX0V2bC1PZw?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Stock: Buying The Projected Growth For 2026 (NASDAQ:COLL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPWWktUDl5c3B5aHRfSXlvZEJJR3lmRXpSbVduNlVZZlZoZjBoV2wwSGVrSF9xY2YtVnpRd3hXQzZ4eUcxWEVodDlBSml3MW1jcHVzV3ZsMTRDUGcyX2hIeERyMGFTNFhYLXJBZ2diekp5dEgyV2VHUmNSUlV4andTVzE3VEJOMVVJdi1mWFQzaFNrZ1BBSnpmZUZiSGFWbk5leTlKZQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical Inc (COLL) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9aS3psWlk5LUtNdklxeVhrQ25UeFhsTk50QTdjekY2UTJJcWxDYnZGTkRjTkJEVGhHOFlBUWk0MGR4dkkySGF1LWtIY1F3ZWNRT05GR1JlOA?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:38:59+00:00", "published_display": "13 Jan 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Provides 2026 Financial Guidance and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYjltV0MzeWRhUU9nclQtdlBjbllpdlplTURka1B1VmRCNmtoX3dtUVBvR3dhWFkxeFRBaG5QS2lEWC1fQVhwNlBPUGlLbWtGSWZpa1l6SnM4Tlc4RDhtNkF4MFVEYmRna1p5VHFaNnNiOHZNNnBXcE5fcl84ODNGbzlkVlotcmwxZGZCOGk3Q1d5SDk5UzhNdVdic2luV0hIWDY1ZXRyTVV6U0tRWGdtSTdUZzRpckVzS2U3SE9TT0lyWFpHR2xEWThoeWJSUWs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Expands Shareholder Returns With Fresh $150M Stock Buyback After Returning $222M Since 2021", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQOFZJUU1YdFdpbzI1Wk56UFlBbC1vaU1zLVcxTV9jd1pVdXRROWo4NlNaSGlPejYxN1pVN3pieFBpTVpCSVQwejFnX0J2TFNZU2FJYnJjQTBHRmhiMHRrMjNTN2g3ZzRuSmtVQ2tKWF9fUmVhQ2FYUjVfRmlJR0k0aE1DdE5ycmtiQ0JrYkR0SW05VURBUnNIakNOX1d1MFNRMkxacnZB?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-07T07:00:00+00:00", "published_display": "07 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Collegium Pharmaceutical, Inc._December 31, 2024", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNl8wZHJxUGtLRUp1VmNpbVRzdWw3SVpBZlV0TkM5NnVpc1RyZ1RCZzdodm1iOF9fRE85R2I2N3ZqUHNWRkZVejVQQXhaV2hYNGpWV0xLSGNxUnN3dE1uZks4UkU2aUFPcTZubEtDY0pTYlNmNHgweGRycy1xRTV3TEJtMVFNZ2NuMGd3SW10TlFnQQ?oc=5", "source_name": "SEC.gov", "published_at": "2025-02-27T23:31:13+00:00", "published_display": "27 Feb 2025 23:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 50, "sentiment_summary": {"positive": 16, "negative": 4, "neutral": 30, "score": 54, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 33.54, "latest_week": "2026-06-19", "one_week_move": -3.2, "four_week_move": -1.6, "twelve_week_move": 3.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.258013, "market_dynamics_buy_signal": false, "relative_strength": -27.489684, "fair_value_gap": 1.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.8761, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, -1.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "Market source", "count": 10}, {"label": "Simply Wall Street", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "GlobeNewswire", "count": 2}, {"label": "Stock Traders Daily", "count": 1}, {"label": "lwvtexas.org", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.2% over one week, -1.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Did Collegium Pharmaceutical\u2019s Profitability Surge and Efficiency Gains Just Shift COLL\u2019s Investment Narrative?"}], "updated_at": "2026-06-22T17:00:32.262503+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}